Arrowstreet Capital
DRNA

Arrowstreet Capital’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Arrowstreet Capital’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-141,001
Closed -$3.11M – 2662
2020
Q4 		$3.11M Sell
141,001
-3,577
-2% -$78.8K ﹤0.01% 1423
2020
Q3 		$2.6M Buy
144,578
+124,378
+616% +$2.58M ﹤0.01% 1451
2020
Q2 		$513K Buy
+20,200
New +$435K ﹤0.01% 1958
2020
Q1 		– Sell
-199,801
Closed -$4.4M – 2218
2019
Q4 		$4.4M Buy
+199,801
New +$4.02M 0.01% 894

Other funds holding DRNA

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Arrowstreet Capital's DRNA Position: Q1 2021 in Review

Arrowstreet Capital sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q1 2021, closing a stake of 141,001 shares — an estimated $3.11M sold.

Arrowstreet Capital first reported a position in DRNA in Q4 2019 and held it in 4 quarters. The position peaked at $4.4M in Q4 2019. 183 funds tracked by Wall St. Rank hold DRNA as of Q1 2021.

  • Arrowstreet Capital reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q1 2021 after selling out during the quarter.
  • Arrowstreet Capital sold 141,001 Dicerna Pharmaceuticals, Inc. shares in Q1 2021, an estimated $3.11M.
  • Arrowstreet Capital first reported a position in Dicerna Pharmaceuticals, Inc. in Q4 2019 and held it in 4 quarters.
  • Arrowstreet Capital's Dicerna Pharmaceuticals, Inc. position peaked at $4.4M in Q4 2019.
  • 183 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q1 2021.

Based on Arrowstreet Capital's 13F filing for Q1 2021, filed 14 May 2021.